Formulations of phosphoramidate derivatives of nucleoside drugs
US-2025302859-A1 · Oct 2, 2025 · US
This page is not indexed by search engines while we improve data quality.
Griffith Hugh patents
Griffith Hugh is listed as an inventor on 53 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Griffith Hugh |
| Total patents | 53 |
| First publication | Sep 27, 2018 |
| Latest publication | Oct 2, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
Formulations of phosphoramidate derivatives of nucleoside drugs
US-12357652-B2 · Jul 15, 2025 · US
Synthesis of phosphate derivatives
US-2025171487-A1 · May 29, 2025 · US
2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
US-2025163096-A1 · May 22, 2025 · US
Treatment regimens
US-2024293439-A1 · Sep 5, 2024 · US
Synthesis of phosphate derivatives
US-12054511-B2 · Aug 6, 2024 · US
2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds
US-12054510-B2 · Aug 6, 2024 · US
Formulations of phosphoramidate derivatives of nucleoside drugs
US-2024082287-A1 · Mar 14, 2024 · US
Formulations of phosphoramidate derivatives of nucleoside drugs
US-11786544-B2 · Oct 17, 2023 · US
Formulation comprising a gemcitabine-prodrug
US-11707477-B2 · Jul 25, 2023 · US
Recent patents
Latest publications not already listed above.
Cancer treatments based on gemcitabine prodrugs
US-2023226092-A1 · Jul 20, 2023 · US
Cancer treatments
US-2023218655-A1 · Jul 13, 2023 · US
Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
US-2023192750-A1 · Jun 22, 2023 · US
Combination therapy
US-2023149436-A1 · May 18, 2023 · US
Gemcitabine prodrugs
US-11629164-B2 · Apr 18, 2023 · US
Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
US-11560400-B2 · Jan 24, 2023 · US
Synthesis of phosphate derivatives
US-2022402962-A1 · Dec 22, 2022 · US
Combination therapy for cancer
US-2022323475-A1 · Oct 13, 2022 · US
2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
US-2022306675-A1 · Sep 29, 2022 · US
Synthesis of phosphate derivatives
US-11414452-B2 · Aug 16, 2022 · US
Cancer treatments
US-11400107-B2 · Aug 2, 2022 · US
Crystalline form of gemcitabine
US-11377467-B2 · Jul 5, 2022 · US
2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds
US-11352387-B2 · Jun 7, 2022 · US
Formulations of phosphoramidate derivatives of nucleoside drugs
US-2022031728-A1 · Feb 3, 2022 · US
Formulation comprising a gemcitabine-prodrug
US-2022031727-A1 · Feb 3, 2022 · US
Salt of triphosphate phosphoramidates of nucleotides as anticancer compounds
US-2022024963-A1 · Jan 27, 2022 · US
Crystalline form of gemcitabine
US-2021188893-A1 · Jun 24, 2021 · US
Formulation comprising a gemcitabine-prodrug
US-11040051-B2 · Jun 22, 2021 · US
Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
US-2021171566-A1 · Jun 10, 2021 · US
Phosphoramidate nucleoside derivatives as anticancer agents
US-2021130387-A1 · May 6, 2021 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| NuCana plc | 53 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61P35/00 | 48 |
| A61K31/7068 | 29 |
| A61P35/02 | 28 |
| A61K9/0019 | 21 |
| C07H19/10 | 20 |